(TAK) Takeda Pharmaceutical Company Limited BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TAK) Takeda Pharmaceutical Company Limited Complete Analysis Pack
Download Your Competitive Advantage
This Takeda Pharmaceutical Company Limited BCG Matrix is a ready-made tool for understanding how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual report content, so you can review what you’ll receive before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
Entyvio global IBD leader
Entyvio is Takeda Pharmaceutical Company Limited’s flagship biologic for ulcerative colitis and Crohn’s disease, and it stays a Star because IBD affects over 7 million people worldwide. Takeda sells it in more than 70 countries, and the drug has kept strong global brand pull as biologic use keeps rising. That broad reach and durable demand make Entyvio Takeda’s key growth engine.
Takhzyro HAE prophylaxis leader
Takhzyro stays a leading hereditary angioedema prophylaxis drug, with trials showing up to a 91% median reduction in attack rate on 300 mg every 2 weeks. HAE affects about 1 in 50,000 people, and better diagnosis is pushing more patients into preventive care. That makes Takhzyro a strong Star in a specialty market that is still expanding.
Takecab Japan P-CAB franchise
Takecab Japan is a Star for Takeda Pharmaceutical Company Limited: it is a first-in-class potassium-competitive acid blocker and keeps a strong domestic share in acid-related disorders. In FY2025, the brand kept expanding through new uses, including reflux and H. pylori regimens, as physician adoption widened. High share plus continued growth keeps this franchise in the Star quadrant.
Adcetris CD30 lymphoma standard
Adcetris is still a core CD30 lymphoma brand for Takeda Pharmaceutical Company Limited, with use in Hodgkin lymphoma and systemic ALCL and ongoing demand in earlier-line and combination regimens. In Takeda Pharmaceutical Company Limited’s FY2024 results, Adcetris stayed a meaningful oncology contributor, supporting a high-share position in a niche market that still expands as treatment moves earlier.
- CD30-positive lymphomas remain the core use case
- Earlier-line regimens keep the market active
- Combination use supports continued clinical demand
- High-share oncology asset for Takeda Pharmaceutical Company Limited
Livtencity CMV transplant therapy
Livtencity is a first-in-class CMV treatment for transplant patients with refractory infection, and it fits a Star profile because demand is still early but rising. In the SOLSTICE study, 55.7% of patients hit the primary endpoint at week 8 versus 23.9% on the comparator, supporting share gains in a niche with clear unmet need.
- First-in-class for refractory CMV
- Week-8 response: 55.7% vs 23.9%
- Adoption is still early
- High growth, niche market
Takeda’s Top Brands Deliver Strong Growth and Market Share
Takeda Pharmaceutical Company Limited’s Stars are Entyvio, Takhzyro, Takecab, Adcetris, and Livtencity. Entyvio leads with 7M+ IBD patients globally; Takhzyro cut HAE attack rates by up to 91%; Takecab kept growing in FY2025; Livtencity’s week-8 response was 55.7% vs 23.9%. These brands combine high share with clear growth.
| Brand | Key data |
|---|---|
| Entyvio | 70+ countries; 7M+ IBD patients |
| Takhzyro | Up to 91% attack-rate cut |
What is included in the product
Detailed Word Document
Takeda’s BCG Matrix maps each business unit to guide invest, hold, or divest decisions across growth and profit pools.
Editable Excel File
One-page Takeda BCG Matrix for quick portfolio clarity and faster decisions
Reference Sources
Shows Takeda Pharmaceutical Company Limited reference sources, giving a credible trail that supports faster, better-informed decisions.
Cash Cows
Gammagard Liquid/Kiovig plasma IG
Gammagard Liquid and Kiovig are mature immunoglobulin brands with repeat dosing and a sticky patient base, so demand is steady rather than fast-growing. They fit Takeda Pharmaceutical Company Limited's cash cow bucket: low growth, strong share, and predictable cash flow.
In 2025, Takeda Pharmaceutical Company Limited's plasma-derived therapy portfolio remained a core earnings driver, with immunoglobulin use tied to chronic immune deficiency and neurology care.
That installed base matters: once patients start therapy, dosing often continues for years, which keeps revenue resilient even when unit growth stays modest.
Hyqvia subcutaneous IG
HyQvia supports chronic primary and secondary immunodeficiency patients on long-term subcutaneous Ig therapy, with infusions typically every 3-4 weeks. The franchise sits in a mature, retention-heavy market, so Takeda can harvest steady cash flow with limited promotional spend. That fits a classic Cash Cow in the BCG matrix, since repeat use and stable demand drive durable revenue.
Cuvitru SCIG franchise
Cuvitru is a mature subcutaneous immunoglobulin franchise in Takeda Pharmaceutical Company Limited’s portfolio, serving a repeat-use specialty market where refills are steady and demand is predictable. In Takeda Pharmaceutical Company Limited’s FY2025, net sales were JPY 4,581.5 billion and adjusted operating profit was JPY 1,035.0 billion, showing strong cash generation. That makes Cuvitru a classic Cash Cow: low growth, dependable cash flow.
Advate hemophilia A factor
Advate is a long-standing recombinant factor VIII therapy for hemophilia A, and Takeda still benefits from an entrenched patient base in chronic prophylaxis. Even with slower growth versus newer treatments, it remains a high-margin, highly monetized brand in a disease that needs lifelong care. Takeda’s FY2025 net sales were ¥4.58 trillion, underscoring the scale that mature brands like Advate still support.
- Installed base keeps volume sticky.
- Growth is mature, not fast.
- High pricing supports cash generation.
Elaprase/Replagal enzyme replacement
Elaprase and Replagal fit Takeda Pharmaceutical Company Limited’s cash cow bucket because both treat ultra-rare lysosomal storage diseases with lifelong, every-2-week infusions, which supports sticky, repeat demand and low churn. Elaprase is approved in more than 40 countries for Hunter syndrome, while Replagal is used in the EU and other markets for Fabry disease, where prevalence is only about 1 in 100,000 to 1 in 117,000. Limited competition and long treatment durations keep cash flow steady without heavy growth capex.
- Ultra-rare patient pools
- Chronic infusion demand
- Low competitive pressure
- Stable, recurring revenue
Takeda’s Cash Cows Power Steady Growth
Takeda Pharmaceutical Company Limited's cash cows are mature, repeat-use brands like Gammagard Liquid, HyQvia, Cuvitru, Advate, Elaprase, and Replagal. Their chronic or ultra-rare use keeps demand sticky and cash flow steady, while FY2025 Takeda Pharmaceutical Company Limited net sales reached JPY 4,581.5 billion and adjusted operating profit JPY 1,035.0 billion.
| Brand | Why it is a cash cow |
|---|---|
| Gammagard Liquid | Repeat Ig dosing |
| HyQvia | 3-4 week chronic use |
| Advate | Lifelong hemophilia care |
Get Your Copy
Takeda Pharmaceutical Company Limited Reference Sources
You're previewing the exact Takeda Pharmaceutical Company Limited BCG Matrix document you'll receive after purchase. What you see here is the same fully formatted file, with no demo content or placeholder pages. Once purchased, the report is instantly available for download and ready to use. It’s a clean, professional document designed for immediate business or strategy work.
Dogs
Natpara discontinued
Natpara was removed from normal commercial use after repeated safety and supply failures, including a 2019 U.S. recall and a long-running supply interruption. By FY2025, it had no meaningful growth profile and no material revenue contribution for Takeda Pharmaceutical Company Limited. It is a clear Dog in the BCG Matrix and a capital trap, with zero strategic upside and ongoing legacy burden.
Alofisel Europe exit
Alofisel never built durable traction in Europe for complex Crohn’s-related fistulas, so Takeda ended commercialization after weak uptake and disappointing results. With a very small niche market and no growth engine, it fits the Dogs bucket. FY2025 Takeda net sales were ¥4.58 trillion, while Alofisel’s impact was immaterial.
Exkivity low uptake
Exkivity never gained broad adoption in EGFR exon 20 insertion NSCLC, and Takeda withdrew the U.S. product in 2023 after the confirmatory trial missed its key endpoint. With competing options and limited differentiation, the asset generated no meaningful sales by FY2025 and fits the Dog category.
Dexilant generic erosion
Dexilant is a classic "Dog" in Takeda Pharmaceutical Company Limited’s BCG Matrix: long patent erosion and generic entry have stripped pricing power, and the acid-suppression market is crowded with cheaper PPIs. That means low growth, fading volume, and shrinking share versus FY2025-era mature GI peers.
Generic pressure caps margins.
Volume weakens in a crowded class.
Share declines as price falls.
Vyvanse US generic pressure
Vyvanse turned into a Dog after U.S. generic lisdexamfetamine entered in August 2023, triggering a fast sales slide for Takeda Pharmaceutical Company Limited. Even with ADHD still a large U.S. market, Vyvanse no longer shows growth, so the brand now acts like a low-share, low-growth asset. In FY2025, the business remained under heavy generic pressure and did not regain momentum.
- Generic entry: August 2023
- US share fell sharply
- FY2025 growth stayed weak
Takeda’s Dogs: Low-Growth Legacy Assets With Little Value
Takeda Pharmaceutical Company Limited’s Dogs are legacy assets with weak or no FY2025 growth, shrinking share, and little capital value. Natpara, Alofisel, and Exkivity now contribute immaterial sales, while Dexilant and Vyvanse face severe erosion from patent loss and generic entry, making them low-return, low-growth holds.
| Asset | FY2025 view |
|---|---|
| Natpara | Zero material sales |
| Alofisel | Immaterial |
| Exkivity | Withdrawn |
| Dexilant | Generic erosion |
| Vyvanse | Post-generic decline |
Question Marks
Fruzaqla 2025 mCRC launch
Fruzaqla is a very recent metastatic colorectal cancer launch for Takeda Pharmaceutical Company Limited, so its BCG position is still a Question Mark. mCRC is a large, hard-fought market with crowded biologic and targeted rivals, and Takeda’s share is still in the build phase. It will need heavy launch spend and strong uptake in 2025 to move toward Star status.
Qinlock Deciphera 2024 asset
Qinlock entered Takeda Pharmaceutical Company Limited through the 2024 Deciphera acquisition, a deal valued at about $2.4 billion in equity. In Deciphera’s 2024 results, Qinlock net product sales were $139.4 million, up 27% year over year, but it still serves a niche GIST market. The asset has growth room, yet its share is still being built, so it fits as a question mark, not a market leader.
Alunbrig ALK NSCLC challenger
Alunbrig remains a challenger in ALK-positive NSCLC, a class that keeps expanding as more patients are diagnosed earlier and treated longer. Takeda still trails bigger rivals in share, while competitors like Alecensa, Xalkori and Lorbrena keep pressure high. In Takeda’s FY2025 results, Alunbrig still needed more uptake and broader label reach to move out of Question Mark territory.
Adynovate/Adynovi factor VIII
Adynovate and Adynovi are in Takeda Pharmaceutical Company Limited’s Question Mark zone: hemophilia B and A treatment still has room, but non-factor drugs and gene therapies are taking share. Takeda has not shown a dominant, cash-cow level position here, so growth depends on faster uptake.
In 2025, the hemophilia class kept shifting toward longer-acting and one-time options, which makes factor VIII products more vulnerable. That means Adynovate/Adynovi can still sell, but the brand needs stronger prescription growth to avoid drifting into a weaker BCG position.
- Growth exists, but share is not dominant
- Non-factor and gene therapy pressure is rising
- Needs better adoption to stay relevant
Gattex/Revestive SBS growth
Gattex/Revestive targets short bowel syndrome, a rare niche that can expand as diagnosis and treatment rates rise; SBS is still underrecognized, so volume can grow from a small base.
Takeda’s share is limited, and with no clear scale edge, the asset fits a 2025 question mark: high upside if penetration improves, but not yet a market leader.
- Rare, underdiagnosed SBS supports growth
- Share remains limited versus potential
- Question mark: growth possible, not proven
Takeda’s Question Marks Need Faster Growth to Become Stars
Takeda Pharmaceutical Company Limited’s Question Marks are newer or niche assets with growth upside, but none yet hold clear market leadership. Fruzaqla and Qinlock are still scaling, while Alunbrig, Adynovate/Adynovi, and Gattex/Revestive face tougher share battles in 2025. They need faster uptake to move toward Star status.
| Asset | 2025 signal | BCG fit |
|---|---|---|
| Fruzaqla | New mCRC launch | Question Mark |
| Qinlock | $139.4M sales, +27% | Question Mark |
| Alunbrig | Still trails rivals | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.